Scholarlink

Background <p>Ovarian cancer (OC) has a poor prognosis and lacks precise biomarkers and therapeutic targets. The tumor-suppressing effects of miR-325 and ARRDC3 have been demonstrated in multiple cancer types, but their association and mechanisms in OC remain unclear.</p> Objective <p>Investigate the prognostic value of miR-325 in OC, clarify its regulatory relationship with ARRDC3, and elucidate its mechanism of action in tumor progression.</p> Methods <p>Detect the expression of miR-325 and ARRDC3 in OC tissue, normal tissue, and A2780 and CAOV-3 cells, and analyze their association with pathological features and prognosis using clinical data. Assess malignant phenotypes, such as proliferation and apoptosis, through the intervention of miR-325 mimic/inhibitor in cells. Validate the direct binding relationship between the two using a dual luciferase reporter assay.</p> Results <p>miR-325 and ARRDC3 are markedly downregulated in OC tissues and cells, with a strong positive correlation between their expression levels in OC tissues. Low miR-325 expression correlates with poor tumor differentiation, advanced FIGO stage, lymph node metastasis, and a poor prognosis in patients, and serves as an independent prognostic factor. Overexpression of miR-325 inhibits OC cell proliferation and invasion. A dual luciferase assay confirms that miR-325 binds to the 3’UTR of ARRDC3, thereby suppressing its expression.</p> Conclusions <p>miR-325 is downregulated in OC and holds prognostic value. Targeting ARRDC3 expression provides new evidence for OC prognosis assessment and molecular mechanism research.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

miR-325 serves as a prognostic biomarker and regulates tumor progression by targeting ARRDC3 in ovarian cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月19日

查看全文
  • Huixian Han,
  • Guohua Qie,
  • Dixia Hu,
  • Wenqiang Wang,
  • Yanjun Yue,
  • Linchen Li,
  • Yan Lei

摘要

Background

Ovarian cancer (OC) has a poor prognosis and lacks precise biomarkers and therapeutic targets. The tumor-suppressing effects of miR-325 and ARRDC3 have been demonstrated in multiple cancer types, but their association and mechanisms in OC remain unclear.

Objective

Investigate the prognostic value of miR-325 in OC, clarify its regulatory relationship with ARRDC3, and elucidate its mechanism of action in tumor progression.

Methods

Detect the expression of miR-325 and ARRDC3 in OC tissue, normal tissue, and A2780 and CAOV-3 cells, and analyze their association with pathological features and prognosis using clinical data. Assess malignant phenotypes, such as proliferation and apoptosis, through the intervention of miR-325 mimic/inhibitor in cells. Validate the direct binding relationship between the two using a dual luciferase reporter assay.

Results

miR-325 and ARRDC3 are markedly downregulated in OC tissues and cells, with a strong positive correlation between their expression levels in OC tissues. Low miR-325 expression correlates with poor tumor differentiation, advanced FIGO stage, lymph node metastasis, and a poor prognosis in patients, and serves as an independent prognostic factor. Overexpression of miR-325 inhibits OC cell proliferation and invasion. A dual luciferase assay confirms that miR-325 binds to the 3’UTR of ARRDC3, thereby suppressing its expression.

Conclusions

miR-325 is downregulated in OC and holds prognostic value. Targeting ARRDC3 expression provides new evidence for OC prognosis assessment and molecular mechanism research.